Full Press Release Details
InflaRx Completes Enrollment in Phase IIb
with Lead Candidate IFX-1 in Hidradenitis Suppurativa
Trial Results Anticipated First Half 2019
Jena, Germany, November 08, 2018
- InflaRx N.V. (Nasdaq:IFRX), a
biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases by targeting the
complement system, a key component of the innate immune system, today announced that patient enrollment has been completed in
the phase IIb study to determine the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a
antibody, in patients suffering from moderate or severe Hidradenitis Suppurativa (HS). HS is a painful and debilitating
chronic inflammatory skin disease with limited treatment options.
The randomized, double-blind, placebo-controlled,
multicenter study is being conducted at 38 sites in both North America and Europe. Following a placebo-controlled, double-blind
period of 16 weeks investigating four different IFX-1 dosing arms plus one placebo arm, there is a 28-week open-label extension
phase to assess long-term efficacy and safety. The primary endpoint is dose response signal, assessed by the Hidradenitis Suppurativa
Clinical Response (HiSCR) score, at week 16. Additional objectives include the evaluation of safety and tolerability of IFX-1,
as well as an assessment of additional efficacy and patient-reported outcome parameters. Topline results from the trial are expected
in the first half of 2019.
Othmar Zenker, M.D., Chief Medical Officer
of InflaRx, said: "We are very pleased to have completed enrollment in this Phase IIb trial within our stated timeframe.
Following the promising results we observed in our earlier trial with IFX-1 in Hidradenitis Suppurativa, our goal with this phase
IIb study is to determine the optimal dose regimen, as well as assess both long-term efficacy and safety of IFX-1 in patients with
Prof. Dr. med. Evangelos J. Giamarellos-Bourboulis,
of the ATTIKON University Hospital in Athens, Greece, the principal investigator of this trial, said: "Hidradenitis Suppurativa
is a debilitating, painful and frequently life-long disease. For patients with moderate to severe HS, treatment options are limited,
and there is an urgent need to find more effective therapies. The C5a blockade with IFX-1 offers an entirely new mode of action
to tackle this disease, and I look forward to seeing the results from this study."
IFX-1 is a first-in-class monoclonal anti-complement
factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards
its target in human blood. Thus, IFX-1 leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism,
which is not the case for molecules blocking the cleavage of C5. IFX-1 has been demonstrated to control the inflammatory response
driven tissue and organ damage by specifically blocking C5a as a key "amplifier" of this response in pre-clinical studies.
IFX-1 is the first monoclonal anti-C5a antibody introduced into clinical development and has, to date, successfully completed three
clinical phase II studies. Until today, more than 150 people have been treated with IFX-1 within completed clinical trials, which
was well tolerated. IFX-1 is currently being developed for various inflammatory indications, including Hidradenitis Suppurativa
and ANCA-associated vasculitis.
InflaRx (Nasdaq:IFRX)
is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class,
potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide
variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in
Jena and Munich, Germany as well as Ann Arbor, Michigan.
Head of Corporate Development and Strategy
Jordan.silverstein[at]inflarx.de
Katja Arnold, Laurie Doyle, Andreas Jungfer
inflarx[at]mc-services.eu
FORWARD LOOKING STATEMENTS
This press release contains forward-looking
statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by
terms such as "may," "will," "should," "expect," "plan," "anticipate,"
"could," "intend," "target," "project," "estimate," "believe,"
"estimate," "predict," "potential" or "continue" and similar expressions. Forward-looking
statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections,
outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and
clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our
product candidates, our intellectual property position, our ability to develop commercial functions, expectations regarding clinical
trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies,
the industry in which we operate, the trends that may affect the industry or us and the risks uncertainties and other factors described
under the heading "Risk Factors" in InflaRx's periodic filings with the Securities and Exchange Commission. These
statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance or achievements to be materially different from any future results, performance
or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you
should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking
statements, even if new information becomes available in the future, except as required by law.